Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney

American Journal of Physiology - Endocrinology and Metabolism

Volumn 302, Issue 8, 2012, Pages

  Grobe, Nadja ^a   Elased, Khalid M ^a   Cool, David R ^a   Morris, Mariana ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Aminopeptidase A; Angiotensin converting enzyme 2; Matrix assisted laser desorption ionization imaging; Prolyl carboxypeptidase; Prolyl endopeptidase

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN III; ANGIOTENSIN[1-4]; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUTAMATE PHOSPHONATE; GLUTAMYL AMINOPEPTIDASE; MLN 4760; PEPTIDASE; PROLYL CARBOXYPEPTIDASE; PROLYL ENDOPEPTIDASE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HORMONE METABOLISM; KIDNEY MEDULLA; KIDNEY PARENCHYMA; MALE; MASS SPECTROMETRY; MICRODISSECTION; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; TISSUE DISTRIBUTION;

ANGIOTENSIN II; ANGIOTENSIN III; ANGIOTENSINS; ANIMALS; IMAGE PROCESSING, COMPUTER-ASSISTED; KIDNEY; KIDNEY CORTEX; KIDNEY MEDULLA; KINETICS; MALE; MICE; MICE, INBRED C57BL; MOLECULAR IMAGING; OSMOLAR CONCENTRATION; PEPTIDE FRAGMENTS; PROTEASE INHIBITORS; PROTEOLYSIS; RENIN-ANGIOTENSIN SYSTEM; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84859451128     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00515.2011     Document Type: Article

References (63)

1. Alfie J, Aparicio LS, Waisman GD. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition. Rev Recent Clin Trials 6: 134-146, 2011.
2. Allred AJ, Diz DI, Ferrario CM, Chappell MC. Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues. Am J Physiol Renal Physiol 279: F841-F850, 2000.
3. Arthur JM, Thongboonkerd V, Scherzer JA, Cai J, Pierce WM, Klein JB. Differential expression of proteins in renal cortex and medulla: a proteomic approach. Kidney Int 62: 1314-1321, 2002.
4. Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 8: 529-535, 2007.
5. Bodineau L, Frugière A, Marc Y, Claperon C, Llorens-Cortes C. Aminopeptidase A inhibitors as centrally acting antihypertensive agents. Heart Fail Rev 13: 311-319, 2008.
6. Bodineau L, Frugière A, Marc Y, Inguimbert N, Fassot C, Balavoine F, Roques B, Llorens-Cortes C. Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension 51: 1318-1325, 2008.
7. Brosnihan KB, Neves LA, Joyner J, Averill DB, Chappell MC, Sarao R, Penninger J, Ferrario CM. Enhanced renal immunocytochemical expression of Ang-(1-7) and ACE2 during pregnancy. Hypertension 42: 749-753, 2003.
8. Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem 69: 4751-4760, 1997.
9. Cervenka L, Mitchell KD, Oliverio MI, Coffman TM, Navar LG. Renal function in the AT1A receptor knockout mouse during normal and volume-expanded conditions. Kidney Int 56: 1855-1862, 1999.
10. Chaurand P, Stoeckli M, Caprioli RM. Direct profiling of proteins in biological tissue sections by MALDI mass spectrometry. Anal Chem 71: 5263-5270, 1999.
11. Cohen SL, Chait BT. Influence of matrix solution conditions on the MALDI-MS analysis of peptides and proteins. Anal Chem 68: 31-37, 1996.
12. Cui L, Nithipatikom K, Campbell WB. Simultaneous analysis of angiotensin peptides by LC-MS and LC-MS/MS: metabolism by bovine adrenal endothelial cells. Anal Biochem 369: 27-33, 2007.
13. da Silveira KD, Pompermayer Bosco KS, Diniz LR, Carmona AK, Cassali GD, Bruna-Romero O, de Sousa LP, Teixeira MM, Santos RA, Simões e Silva AC, Ribeiro Vieira MA. ACE2-angiotensin-(1-7)-Mas axis in renal ischaemia/reperfusion injury in rats. Clin Sci (Lond) 119: 385-394, 2010.
14. Dales NA, Gould AE, Brown JA, Calderwood EF, Guan B, Minor CA, Gavin JM, Hales P, Kaushik VK, Stewart M, Tummino PJ, Vickers CS, Ocain TD, Patane MA. Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc 124: 11852-11853, 2002.
15. del Pilar Carrera M, Ramírez-Expósito MJ, Mayas MD, García MJ, Martínez-Martos JM. Mammary renin-angiotensin system-regulating aminopeptidase activities are modified in rats with breast cancer. Tumour Biol 31: 583-588, 2010.
16. Der Sarkissian S, Huentelman MJ, Stewart J, Katovich MJ, Raizada MK. ACE2: A novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol 91: 163-198, 2006.
17. Elased KM, Cool DR, Morris M. Novel mass spectrometric methods for evaluation of plasma angiotensin converting enzyme 1 and renin activity. Hypertension 46: 953-959, 2005.
18. Elased KM, Cunha TS, Gurley SB, Coffman TM, Morris M. New mass spectrometric assay for angiotensin-converting enzyme 2 activity. Hypertension 47: 1010-1017, 2006.
19. Fountoulakis M, Hardmeier R, Hoger H, Lubec G. Postmortem changes in the level of brain proteins. Exp Neurol 167: 86-94, 2001.
20. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 264: 224-236, 2008.
21. Giani JF, Muñoz MC, Pons RA, Cao G, Toblli JE, Turyn D, Dominici FP. Angiotensin-(1-7) reduces proteinuria and diminishes structural damage in renal tissue of stroke-prone spontaneously hypertensive rats. Am J Physiol Renal Physiol 300: F272-F282, 2011.
22. Gonzalez-Villalobos RA, Seth DM, Satou R, Horton H, Ohashi N, Miyata K, Katsurada A, Tran DV, Kobori H, Navar LG. Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice. Am J Physiol Renal Physiol 295: F772-F779, 2008.
23. Goodwin RJ, Lang AM, Allingham H, Borén M, Pitt AR. Stopping the clock on proteomic degradation by heat treatment at the point of tissue excision. Proteomics 10: 1751-1761, 2010.
24. Goodwin RJ, Pennington SR, Pitt AR. Protein and peptides in pictures: imaging with MALDI mass spectrometry. Proteomics 8: 3785-3800, 2008.
25. Greis KD. Mass spectrometry for enzyme assays and inhibitor screening: an emerging application in pharmaceutical research. Mass Spectrom Rev 26: 324-339, 2007.
26. Gurley SB, Allred A, Le TH, Griffiths R, Mao L, Philip N, Haystead TA, Donoghue M, Breitbart RE, Acton SL, Rockman HA, Coffman TM. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 116: 2218-2225, 2006.
27. Gwathmey TM, Westwood BM, Pirro NT, Tang L, Rose JC, Diz DI, Chappell MC. Nuclear angiotensin-(1-7) receptor is functionally coupled to the formation of nitric oxide. Am J Physiol Renal Physiol 299: F983-F990, 2010.
28. Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 52: 1223-1237, 2006.
29. 2+]i along the rat nephron. Kidney Int 56: 850-859, 1999.
30. Iturrioz X, Rozenfeld R, Michaud A, Corvol P, Llorens-Cortes C. Study of asparagine 353 in aminopeptidase A: characterization of a novel motif (GXMEN) implicated in exopeptidase specificity of monozinc aminopeptidases. Biochemistry 40: 14440-14448, 2001.
31. Jones EA, van RA, van Zeijl RJ, Hogendoorn PC, Bovee JV, Deelder AM, McDonnell LA. Multiple statistical analysis techniques corroborate intratumor heterogeneity in imaging mass spectrometry datasets of myxofibrosarcoma. PLoS One 6: e24913, 2011
32. Karamyan VT, Gembardt F, Rabey FM, Walther T, Speth RC. Characterization of the brain-specific non-AT1, non-AT2 angiotensin binding site in the mouse. Eur J Pharmacol 590: 87-92, 2008.
33. Khairallah PA, Bumpus FM, Page IH, Smeby RR. Angiotensinase with a high degree of specificity in plasma and red cells. Science 140: 672-674, 1963.
34. Lapolla A, Seraglia R, Molin L, Williams K, Cosma C, Reitano R, Sechi A, Ragazzi E, Traldi P. Low molecular weight proteins in urines from healthy subjects as well as diabetic, nephropathic and diabeticnephropathic patients: a MALDI study. J Mass Spectrom 44: 419-425, 2009.
35. Lejczak B, De Choszczak MP, Kafarski P. Inhibition of aminopeptidases by phosphonic acid and phosphinic acid analogues of aspartic and glutamic acids. J Enzyme Inhib 7: 97-103, 1993.
36. Lortie M, Bark S, Blantz R, Hook V. Detecting low-abundance vasoactive peptides in plasma: progress toward absolute quantitation using nano liquid chromatography-mass spectrometry. Anal Biochem 394: 164-170, 2009.
37. McDonnell LA, Heeren RM. Imaging mass spectrometry. Mass Spectrom Rev 26: 606-643, 2007.
38. Monteiro MB, Senador D, Zhang WF, Morris M, Elased KM. Balance of ACE and ACE2 in diabetes: Decreased renal ACE2 activity in hypertensive db/db diabetic mice (Abstract). Hypertension 52: E91, 2008.
39. Nilsson A, Fehniger TE, Gustavsson L, Andersson M, Kenne K, Marko-Varga G, Andrén PE. Fine mapping the spatial distribution and concentration of unlabeled drugs within tissue micro-compartments using imaging mass spectrometry. PLoS One 5: e11411, 2010.
40. Pohl M, Kaminski H, Castrop H, Bader M, Himmerkus N, Bleich M, Bachmann S, Theilig F. Intrarenal renin angiotensin system revisited: role of megalin-dependent endocytosis along the proximal nephron. J Biol Chem 285: 41935-41946, 2010.
41. Rabey FM, Karamyan VT, Speth RC. Distribution of a novel binding site for angiotensins II and III in mouse tissues. Regul Pept 162: 5-11, 2010.
42. Raizada MK, Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 50: 112-119, 2007.
43. Seeley EH, Oppenheimer SR, Mi D, Chaurand P, Caprioli RM. Enhancement of protein sensitivity for MALDI imaging mass spectrometry after chemical treatment of tissue sections. J Am Soc Mass Spectrom 19: 1069-1077, 2008.
44. Sharman DC, Morris AD, Struthers AD. Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus. Diabetologia 50: 2061-2066, 2007.
45. Sköld K, Svensson M, Norrman M, Sjögren B, Svenningsson P, Andrén PE. The significance of biochemical and molecular sample integrity in brain proteomics and peptidomics: stathmin 2-20 and peptides as sample quality indicators. Proteomics 7: 4445-4456, 2007.
46. Song L, Healy DP. Kidney aminopeptidase A and hypertension, part II: effects of angiotensin II. Hypertension 33: 746-752, 1999.
47. Song L, Ye M, Troyanovskaya M, Wilk E, Wilk S, Healy DP. Rat kidney glutamyl aminopeptidase (aminopeptidase A): molecular identity and cellular localization. Am J Physiol Renal Fluid Electrolyte Physiol 267: F546-F557, 1994.
48. Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 7: 493-496, 2001.
49. Stoeckli M, Farmer TB, Caprioli RM. Automated mass spectrometry imaging with a matrix-assisted laser desorption ionization time-of-flight instrument. J Am Soc Mass Spectrom 10: 67-71, 1999.
50. Suckau D, Resemann A, Schuerenberg M, Hufnagel P, Franzen J, Holle A. A novel MALDI LIFT-TOF/TOF mass spectrometer for proteomics. Anal Bioanal Chem 376: 952-965, 2003.
51. Tan F, Morris PW, Skidgel RA, Erdös EG. Sequencing and cloning of human prolylcarboxypeptidase (angiotensinase C). Similarity to both serine carboxypeptidase and prolylendopeptidase families. J Biol Chem 268: 16631-16638, 1993.
52. Tieku S, Hooper NM. Inhibition of aminopeptidases N, A and W. A re-evaluation of the actions of bestatin and inhibitors of angiotensin converting enzyme. Biochem Pharmacol 44: 1725-1730, 1992.
53. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238-33243, 2000
54. Végvári A, Fehniger TE, Gustavsson L, Nilsson A, Andrén PE, Kenne K, Nilsson J, Laurell T, Marko-Varga G. Essential tactics of tissue preparation and matrix nano-spotting for successful compound imaging mass spectrometry. J Proteomics 73: 1270-1278, 2010.
55. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological peptides by human angiotensinconverting enzyme-related carboxypeptidase. J Biol Chem 277: 14838-14843, 2002.
56. Weber MA, Giles TD. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? Rev Cardiovasc Med 7: 45-54, 2006.
57. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24. 11: Life Sci 52: 1461-1480, 1993.
58. Wilk S, Orlowski M. Inhibition of rabbit brain prolyl endopeptidase by n-benzyloxycarbonyl-prolyl-prolinal, a transition state aldehyde inhibitor. J Neurochem 41: 69-75, 1983.
59. Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S, Batlle D. ACE and ACE2 activity in diabetic mice. Diabetes 55: 2132-2139, 2006.
60. Yatabe J, Yoneda M, Yatabe MS, Watanabe T, Felder RA, Jose PA, Sanada H. Angiotensin III stimulates aldosterone secretion from adrenal gland partially via angiotensin II type 2 receptor but not angiotensin II type 1 receptor. Endocrinology 152: 1582-1588, 2011.
61. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 43: 1120-1125, 2004.
62. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 17: 3067-3075, 2006.
63. Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, Corvol P, Llorens-Cortes C. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci USA 93: 11968-11973, 1996.